Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06220422
Other study ID # CHRD0123
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 26, 2024
Est. completion date April 10, 2024

Study information

Verified date June 2024
Source Hôpital NOVO
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to demonstrate that by allowing patients with an anticoagulant level less than 100 ng/ml to have their fracture managed surgically, will reduce the delay in surgery and therefore the complications associated. It will also demonstrate that there are no more complications with this new management than from remaining with a bleeding fracture.


Description:

Fracture of the upper extremity of the femur are constantly on the increase and represent a public health issue in a population with increasing life expectancy. In the majority of cases, this fracture requires rapid surgical treatment, ideally within 48 hours, before complications, associated with the supine position, appear. A prolonged surgical delay is responsible for multiple complications and increase mortality in a potentially comorbid and fragile population. Oral anticoagulants (NACOs) are now widely used in general population for cardiovascular diseases, such as non-valvular atrial fibrillation or thrombo-embolic events. Their activity and circulation rate are assessed by an Anti-Xa assay. The current recommendation for scheduled surgery is an assay with an anti-Xa activity of less than 50 ng/mL. The acquisition of this assay and the wait for a decrease in anti-Xa activity are currently a factor of lengthening the surgical delay leading to proposal a new dosage. By offering the possibility of surgical management with an anti-Xa activity of less than 100 ng/ml, the purpose is to demonstrate a reduction in surgical delay (less than 48 hours) and associated complications. One of the secondary purposes is also to demonstrate that there are no more intra and post-operative complications with this new protocol.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date April 10, 2024
Est. primary completion date April 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria : - Patients on NACO undergoing surgery for fracture of the upper end of the femur, - 18 years and over, - Informed patients who did not object. Exclusion Criteria : - Patients under court protection, - Patients under guardianship/curators .

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Standard Department procedure for managing direct-acting oral anticoagulants
Standard Department procedure for managing direct-acting oral anticoagulants (NACO < 50 ng/mL) in the management of fractures before September 2021
New Department procedure for managing direct-acting oral anticoagulants
New Department procedure for managing direct-acting oral anticoagulants (NACO < 100 ng/mL) in the management of fractures after September 2021

Locations

Country Name City State
France Anaesthetics department - Hôpital NOVO - Pontoise Site Pontoise

Sponsors (1)

Lead Sponsor Collaborator
Hôpital NOVO

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Highlighting of a reduction in the time to surgical management of fracture of the upper end of the femur by adjusting the preoperative threshold for the dosage of of direct-acting oral anticoagulants Comparison of time from hospital admission to surgery (in hours) between both groups At the end of the study, an average of 1 month
Secondary Measure of the impact of the department's new strategy (NACO threshold < 100 ng/mL) on estimated intraoperative blood loss Comparison on the amount of blood lost (mL) between both groups At the end of the study, an average of 1 month
Secondary Description of the impact of the department's new strategy (NACO threshold < 100 ng/mL) on transfusion requirement The impact on transfusion requirements between both groups is evaluate on the following items :
Packed red blood cells,
Fresh frozen plasma,
Unit concentrate of platelets,
4-factor prothrombin complex concentrate.
At the end of the study, an average of 1 month
Secondary Description of the impact of the department's new strategy (NACO threshold < 100 ng/mL) on the hospital morbidity The impact on Hospital morbidity between both groups is evaluate on the following complications :
Infectious complications (surgical site infection, nosocomial infections: urinary, pneumonia, others),
Thromboembolic complications (pulmonary embolism, deep vein thrombosis),
Cardiovascular complications (decompensation of heart failure, Acute pulmonary oedema, ACS),
Post-operative haemorrhagic complications (surgical site haematoma requiring treatment),
30-day readmission
At the end of the study, an average of 1 month
Secondary Measure the impact of the department's new strategy (NACO threshold < 100 ng/mL) on the hospital mortality Comparison on the number of deaths in each group. At the end of the study, an average of 1 month
Secondary Measure of the impact of the department's new strategy (NACO threshold < 100 ng/mL) on the complications affecting surgical management The impact on the factors affecting surgical management between both groups is evaluate on the following item :
- Complications of the supine position (bedsores, etc.) and those related to the field (confusion, physical restraint indwelling catheter, stay in intensive care, resumption walking /chair, delay in returning home, Follow-up care and rehabilitation (SSR), geriatric assessment, nutritional management)
At the end of the study, an average of 1 month
Secondary Measure of the impact of the department's new strategy (NACO threshold < 100 ng/mL) on the degree of dependence due to surgical management The impact on the factors affecting surgical management between both groups is evaluate on the following item :
- Degree of dependence according to the Katz evaluation scale, The KATZ scale is used to determine the degree of dependency of patients. It consists of a questionnaire assessing their abilities in 6 areas of daily life. For each area, the response varies between 4 scores ranging from no assistance to the need for total assistance.
At the end of the study, an average of 1 month
Secondary Measure of the impact of the department's new strategy (NACO threshold < 100 ng/mL) on the factors affecting surgical management The impact on the factors affecting surgical management between both groups is evaluate on the following item :
- Day of admission to care (weekend/holiday/on-call day)
At the end of the study, an average of 1 month
See also
  Status Clinical Trial Phase
Completed NCT03231787 - Clinical Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery N/A
Completed NCT00888160 - Timing of Orthopaedic Surgery in the Multiply-injured Patient: Development of a Protocol for Early Appropriate Care
Completed NCT05613257 - Distal Targeter vs Free-hand N/A
Withdrawn NCT00240396 - Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture N/A
Recruiting NCT01969279 - Radiographic Influences of Bisphosphonate Treatment on Femur N/A
Terminated NCT03160508 - Trochanter Fixation Nail Advanced (TFNA) Weight Bearing
Completed NCT04127045 - ProspEctive Cohort Study on Multidisciplinary Approach to Femur FRactures' manAgement in Over 65 Population
Recruiting NCT03868280 - The FLiP Study, a Pilot Cluster Randomized Trial N/A
Completed NCT00725894 - Pediatric Locking Nail for the Treatment of Femoral Fractures in Children N/A
Recruiting NCT04657510 - Femoral frACturEs and COVID-19.
Completed NCT05225753 - Post-operative Anemia in Lateral Fractures of the Femur.
Active, not recruiting NCT03775408 - FAST: Clinical Feasibility
Completed NCT02793947 - Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures Phase 4
Completed NCT00916136 - Skeletal Versus Cutaneous Traction For Treatment of Femur Fractures N/A
Completed NCT06430944 - Comparative Study Between Single and Double Limb Hip Spica Cast in Fracture Femur in Young Children N/A
Completed NCT05183308 - Combined Drug Therapy in Lateral Fragility Fractures of the Femur
Not yet recruiting NCT00616044 - Continuous Spinal Anesthesia Versus Combined Spinal Epidural Block N/A
Terminated NCT01484405 - Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture N/A
Completed NCT00943332 - Pediatric Femur Research Project
Not yet recruiting NCT00686023 - Comparing Surgical Techniques for CRIF of Pertrochanteric Fractures N/A